Clinical Trials Directory

Trials / Unknown

UnknownNCT01214343

Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC

Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
190 (estimated)
Sponsor
Ministry of Health, Labour and Welfare, Japan · Other Government
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.

Detailed description

Sorafenib with Low-dose FP Group Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) for 28 days. Cisplatin at the dose of 20mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330mg/m2 will be administered continuously at day1-day5, and day8-day12 via the implanted catheter system. Sorafenib Group Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) for 28 days. The treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity.

Conditions

Interventions

TypeNameDescription
DRUGSorafenib with Low-dose FPSorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
DRUGSorafenibSorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.

Timeline

Start date
2010-10-01
Primary completion
2013-09-01
Completion
2013-09-01
First posted
2010-10-05
Last updated
2011-06-15

Locations

30 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT01214343. Inclusion in this directory is not an endorsement.